Explore

Trendline Trendline
Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB

Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB

Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB
Trendline Trendline
Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI
Trendline Trendline
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability
Trendline Trendline
Savara Reports First Quarter Financial Results Highlighting MOLBREEVI Development Progress

Savara Reports First Quarter Financial Results Highlighting MOLBREEVI Development Progress

Savara Reports First Quarter Financial Results Highlighting MOLBREEVI Development Progress
Trendline Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358
Trendline Trendline
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Trendline Trendline
Trisk Bio and NanoMosaic Partner to Enhance AAV Analytics with Tessie Platform

Trisk Bio and NanoMosaic Partner to Enhance AAV Analytics with Tessie Platform

Trisk Bio and NanoMosaic Partner to Enhance AAV Analytics with Tessie Platform
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302